Actualización de valorviernes, 17 de julio de 2026
$UNH Posts 56.4% EPS Jump in Most Recent Quarter
UnitedHealth Group reported EPS of $6.38 vs $4.08 a year ago, a 56.4% jump. Revenue grew 2.0% YoY. ACCE score sits at 60. Here's what the numbers show.
UNH reported earnings for its most recent quarter (reported July 16, 2026), and the headline number is hard to ignore. EPS came in at $6.38, up from $4.08 in the same period a year earlier — a 56.4% year-over-year increase. Revenue grew a more modest 2.0% over the same stretch.
The earnings result came in just ahead of expectations, beating the consensus estimate by 0.3%. The stock trades at $429.75 as of the report date, giving the company a market cap of $384.49B. The trailing P/E sits at 31.9, while the forward P/E drops to 23.5 — a meaningful compression that reflects how much of the earnings recovery the market is now pricing into future periods rather than the past.
We do not have guidance commentary from this report, so any read on the company's own forward expectations is unavailable here.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
What it means
The gap between the 56.4% EPS growth and the 2.0% revenue growth is the most interesting tension in this print. Earnings expanded dramatically on a relatively flat top line, which points to margin improvement or cost reduction rather than volume-driven growth. Net margin stands at 2.7% — thin by most standards — but the direction of travel on earnings per share is clearly positive.
FCF yield of 4.2% adds some substance to the earnings story. Strong earnings quality, as flagged in the ACCE data, suggests the cash generation behind those earnings is real rather than accounting-driven. ROE of 12.2% is respectable for a company operating in a sector with heavy regulatory and cost pressures.
The ACCE score for UNH is 60 out of 100. Breaking that down: Momentum scores 97, which reflects the stock's 46.9% one-year return and recent price strength. Value scores 58 and Quality 52, both middling. Growth scores 31, the weakest component — consistent with a 2.0% revenue expansion that, on its own, would not excite growth-focused screens.
The 6-model fair value estimate sits at $397.95, which is 7.4% below the current price of $429.75. That gap suggests the market is paying a premium relative to where a composite of valuation models would anchor the stock. The analyst consensus target of $437.81 sits above the current price, implying modest upside from that lens — but the two signals point in opposite directions, which is worth noting.
The dividend yield of 2.1% provides some return floor for holders while the valuation picture gets sorted out.
For current price and score updates, see acceinvestments.com/stocks/UNH.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
